Editorial Commentary
The LASRE trial: further support for laparoscopic total mesorectal excision?
Chinese Clinical Oncology
2023;
12
(6)
:58
.
(31 December 2023)
Laparoscopy-assisted vs. open surgery total mesorectal excision in low rectal cancer: commentary on the LASRE trial and review of current evidence
Chinese Clinical Oncology
2023;
12
(6)
:59
.
(31 December 2023)
To radiate or not to radiate: that is the question?—a commentary on “Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial”
Chinese Clinical Oncology
2023;
12
(6)
:60
.
(31 December 2023)
Global efficacy and clinical application of androgen receptor inhibitors in metastatic prostate cancer
Chinese Clinical Oncology
2023;
12
(6)
:61
.
(31 December 2023)
Original Article
Efficacy and safety of PARP inhibitor in non-small cell lung cancer: a systematic review with meta-analysis
Chinese Clinical Oncology
2023;
12
(6)
:62
.
(31 December 2023)
Establishment and validation of a prognostic model for gastric cancer patients of Hebei Province in China
Chinese Clinical Oncology
2023;
12
(6)
:63
.
(31 December 2023)
Review Article
Tumor treating fields: narrative review of a promising treatment modality for cancer
Chinese Clinical Oncology
2023;
12
(6)
:64
.
(31 December 2023)
Twenty-five years with companion diagnostics
Chinese Clinical Oncology
2023;
12
(6)
:65
.
(31 December 2023)
A systematic review of undifferentiated pleomorphic sarcoma of the chest wall
Chinese Clinical Oncology
2023;
12
(6)
:66
.
(31 December 2023)
Advances in understanding and management of high-grade pancreatic neuroendocrine neoplasm: a comprehensive review
Chinese Clinical Oncology
2023;
12
(6)
:67
.
(31 December 2023)
Hyperthermic intraperitoneal chemotherapy for gastric cancer: a narrative review
Chinese Clinical Oncology
2023;
12
(6)
:68
.
(31 December 2023)
Case Report
Case report: durable response of gliomatosis cerebri with concurrent tumor-treating fields (TTFields) and chemoradiotherapy treatment
Chinese Clinical Oncology
2023;
12
(6)
:69
.
(31 December 2023)
Left total pneumonectomy performed after alectinib treatment for anaplastic lymphoma kinase-positive lung adenocarcinoma: a case report
Chinese Clinical Oncology
2023;
12
(6)
:70
.
(31 December 2023)
